Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 120 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Representative confocal image (10 x objective) of individual spheroids fixed, sectioned, and then stained for vimentin (green) and DNA (DAPI, blue). Vimentin protein expression from sections quantitated from multiple replicate spheroid treatments with U0126 and axitinib using ImageJ software.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

    VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck.

    Axitinib treatment blocks VEGFR2 phosphorylation.

    HUVECs were starved O/N in EBM-2 basal medium with 1% FBS and antibiotic. Cells were pre-treated with Axitinib at 0.1, 1 and 10 nM concentrations. VEGF stimulation was 50 ng/ml for 10 minutes before cells were collected and protein isolated for immunoprecipitation with VEGFR2 followed by immunoblotting with VEGFR-2 and phospho-VEGFR-2.

     

     

    Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M1POZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMECwNFUyOyEQvF2= NUnWTlJuW0GQR1XS
NCI-H1703 NW\XS2JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMECwPVAzKM7:TR?= M1XhXXNCVkeHUh?=
KASUMI-1 MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEC2PFIh|ryP M3zwcnNCVkeHUh?=
CGTH-W-1 M4jKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDiSmdKSzVyPUCuNFA4OjJizszN MlLGV2FPT0WU
A204 Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33PWmlEPTB;MD6wNFk6OiEQvF2= MW\TRW5ITVJ?
HOP-62 MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH3WFFKSzVyPUCuNVA5OzZizszN NVLY[4tRW0GQR1XS
H-EMC-SS NWPpcpRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XVR2lEPTB;MD6xNVAxPSEQvF2= NW\YcIV3W0GQR1XS
KU812 NFHuV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3LSoYxUUN3ME2wMlE3PTd5IN88US=> MV;TRW5ITVJ?
EM-2 NHXRUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXhTWM2OD1yLkG2PFE3KM7:TR?= M1vXfnNCVkeHUh?=
LAMA-84 NXf6cId2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTMcYNKSzVyPUCuNVc3PjVizszN M4n3b3NCVkeHUh?=
JAR MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMkO5PFkh|ryP M2HzWnNCVkeHUh?=
G-361 NFjKbHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwM{KzNlUh|ryP NH\ud2JUSU6JRWK=
KG-1 MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jIWGlEPTB;MD6zO|Y1OiEQvF2= MlfyV2FPT0WU
BV-173 NG\LUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwM{mzNkDPxE1? MlvuV2FPT0WU
K5 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\1TWM2OD1yLkSyNVI4KM7:TR?= M{faVXNCVkeHUh?=
MEG-01 NXnDdVN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3q2TWlEPTB;MD60NlM3OSEQvF2= NUTlXGNlW0GQR1XS
MFM-223 M3v4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jnTmlEPTB;MD60OFc4PiEQvF2= M2jYZnNCVkeHUh?=
BE-13 M{HCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnidpc5UUN3ME2wMlUyODB6IN88US=> NUXtWmZmW0GQR1XS
NEC8 NV7ZVGJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7aW3FKSzVyPUCuO|IyOTNizszN Mmj2V2FPT0WU
SW756 M3nmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\JXGlEPTB;MD65PVg1PiEQvF2= NHXBcHZUSU6JRWK=
A2780 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TTPGlEPTB;MT6wNVE1PiEQvF2= NVXNZXp1W0GQR1XS
NB14 NGf4VXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTFwMEG4NFEh|ryP NVPFOYR6W0GQR1XS
H4 NF\ZZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnIcVFWUUN3ME2xMlA3PDJ{IN88US=> NXH1OHNXW0GQR1XS
SK-OV-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXNc4dKSzVyPUGuNFY3OzNizszN MXrTRW5ITVJ?
AN3-CA MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7lTWM2OD1zLkC4N|g6KM7:TR?= M3rrNXNCVkeHUh?=
A427 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLyRnpoUUN3ME2xMlExOzhzIN88US=> NVj5UVZ{W0GQR1XS
ES7 NGfBR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\mdWdKSzVyPUGuNVE{OzRizszN MVHTRW5ITVJ?
AGS M4PISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX62U|UzUUN3ME2xMlEyOzl3IN88US=> NYK5fnRuW0GQR1XS
G-402 NYXPOmloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XRRWlEPTB;MT6xOFY6PCEQvF2= MX3TRW5ITVJ?
ES5 M1TqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrQTWM2OD1zLkG3NlQ5KM7:TR?= M3Oy[3NCVkeHUh?=
DEL NXfTNoh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFwMkW0OVch|ryP MYHTRW5ITVJ?
NB10 M4TlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFwM{K1OVch|ryP MYLTRW5ITVJ?
NCI-H1581 NITTNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jUe2lEPTB;MT6zPVA1OiEQvF2= M{TVenNCVkeHUh?=
D-566MG NGW4VGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHRN25KSzVyPUGuOFA3QDNizszN NFS0e4tUSU6JRWK=
LXF-289 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwNEO5PVYh|ryP MVzTRW5ITVJ?
BT-549 NU\xZ3pzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnrdVRKSzVyPUGuOVY6ODlizszN NV3PXplmW0GQR1XS
NKM-1 M2PjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXvUmVQUUN3ME2xMlYxPTV4IN88US=> MU\TRW5ITVJ?
SW780 NXvxZZlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e0S2lEPTB;MT62OVE2QCEQvF2= NELlc4lUSU6JRWK=
NCI-H292 NGf3VIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDsTWM2OD1zLk[2N|g{KM7:TR?= NF7RbVZUSU6JRWK=
HMV-II NYn6VolmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDxVZJKSzVyPUGuO|A1QDhizszN M1jkbnNCVkeHUh?=
ALL-PO NXOy[GpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjkbYdEUUN3ME2xMlgxODF3IN88US=> MYLTRW5ITVJ?
UACC-257 NUTqVFZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;Yb|JKSzVyPUGuPFIyPjNizszN NFXF[WtUSU6JRWK=
PA-1 MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwOEK3NlUh|ryP MUfTRW5ITVJ?
HD-MY-Z NH32WW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwOE[yPFEh|ryP M1TqfnNCVkeHUh?=
HSC-4 NXXLTpFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFwOUO4N|kh|ryP Ml2zV2FPT0WU
GCT NFuweZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnJbIRKSzVyPUKuNFA6OTZizszN NXfiOVNSW0GQR1XS
RT-112 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJwMUO0NlQh|ryP NV3Me2NbW0GQR1XS
A172 Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1viN2lEPTB;Mj6xN|YxPiEQvF2= NYnveWlXW0GQR1XS
HCE-T M2DvZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXhWXdKSzVyPUKuNlA2QThizszN Mm\QV2FPT0WU
YH-13 NInKO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJwMkG2O|Eh|ryP MnvJV2FPT0WU
DK-MG Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS1[oVrUUN3ME2yMlI{QDN2IN88US=> M3XRW3NCVkeHUh?=
ACN NX;BfFh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojmTWM2OD1{LkKzPFc2KM7:TR?= M3vxRXNCVkeHUh?=
VA-ES-BJ NVew[XZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXmTWM2OD1{LkK0PVU4KM7:TR?= NYnNO5l7W0GQR1XS
L-363 MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LpTWlEPTB;Mj6yPFA3OSEQvF2= MYHTRW5ITVJ?
HuH-7 NEC1dVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJwNEKxOlUh|ryP NELCUlNUSU6JRWK=
A4-Fuk NWqyZ4c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS2V4RKSzVyPUKuOFcyPjhizszN M1TQTnNCVkeHUh?=
T-24 NYLDb5JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki4TWM2OD1{LkS4NFM4KM7:TR?= M4rL[nNCVkeHUh?=
GOTO NWjTOW1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofKTWM2OD1{LkWzNFE{KM7:TR?= NX7YfFk4W0GQR1XS
MV-4-11 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmi1TWM2OD1{LkW5NVY6KM7:TR?= MULTRW5ITVJ?
DMS-114 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nuOmlEPTB;Mj62OlM1PSEQvF2= MXjTRW5ITVJ?
MHH-NB-11 Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXwXZBKSzVyPUKuO|AzQTlizszN NIfD[XZUSU6JRWK=
CHP-212 NXHU[4YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K1VmlEPTB;Mj64NlA6OSEQvF2= MUXTRW5ITVJ?
DMS-273 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjP[oxKSzVyPUKuPVAzODdizszN NIOyN3lUSU6JRWK=
SF295 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTNwMEK1PVch|ryP MoHVV2FPT0WU
NCI-H1563 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT3b5BKSzVyPUOuNVUxODVizszN MYHTRW5ITVJ?
NCI-H446 MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLtNnJWUUN3ME2zMlIzQDB3IN88US=> MmG1V2FPT0WU
HCC1806 M3m1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHwTWM2OD1|LkK3OlU4KM7:TR?= M4XiVHNCVkeHUh?=
SF126 MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTNwM{CwNVch|ryP MmPoV2FPT0WU
SW982 NYLtNJJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNwM{O4O|Uh|ryP MW\TRW5ITVJ?
ES8 NFGxTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT4Z2F{UUN3ME2zMlM1QTl7IN88US=> M2HFTXNCVkeHUh?=
SCC-4 Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTNwNUCzPVYh|ryP Mn;IV2FPT0WU
RPMI-8226 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTNwNkK2NVYh|ryP MkXEV2FPT0WU
EW-11 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTNwNkOwNlIh|ryP NI\F[nFUSU6JRWK=
COR-L105 M1XiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTNwNkOzN|Qh|ryP NG\KeHNUSU6JRWK=
ES1 NFPNeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmf4TWM2OD1|LkizNFk1KM7:TR?= NEDNO2NUSU6JRWK=
KMOE-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fMfmlEPTB;Mz65NVgxQCEQvF2= MWLTRW5ITVJ?
ABC-1 M1fBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHBVYpKSzVyPUOuPVM6OTFizszN NFuxc5RUSU6JRWK=
NCI-H526 M2CwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fxRWlEPTB;Mz65PVEzPiEQvF2= MX;TRW5ITVJ?
HCC1395 M1y1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nvVGlEPTB;Mz65PVQ5PCEQvF2= MYHTRW5ITVJ?
DU-145 M2DKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL5TWM2OD12LkGyPFI2KM7:TR?= NU\IR|VKW0GQR1XS
JEG-3 M3voV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTRwMUW5NVYh|ryP NVPnUJJCW0GQR1XS
HCC1187 NULRbJFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7kS2F1UUN3ME20MlIyPTl5IN88US=> M4nv[XNCVkeHUh?=
LC-2-ad NXXSOHg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRwMkKxO|ch|ryP M2mzPXNCVkeHUh?=
ONS-76 M2f1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTRwMkSxPVIh|ryP NVLuS5Y1W0GQR1XS
CAL-27 M2Tocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTRwMkSzOFQh|ryP MV3TRW5ITVJ?
8-MG-BA NGjLXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXraOWFrUUN3ME20MlI3PjV6IN88US=> MoL0V2FPT0WU
HGC-27 M{TBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PKOWlEPTB;ND6yPVY3KM7:TR?= Ml\yV2FPT0WU
Hs-578-T NF\WNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fzdGlEPTB;ND6zNVQ3QCEQvF2= M{H6UHNCVkeHUh?=
EW-1 MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\rT4RKSzVyPUSuOVMxOTRizszN MYPTRW5ITVJ?
SW1573 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHjTWM2OD12LkW1NVY{KM7:TR?= NYDrbnBZW0GQR1XS
SNU-423 M4TsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTRwNkC3PUDPxE1? MlT2V2FPT0WU
HOS NHPHbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jhSWlEPTB;ND62PVc4KM7:TR?= M3rMbXNCVkeHUh?=
LB1047-RCC MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTRwOEG0NVgh|ryP NV:1dYxyW0GQR1XS
ChaGo-K-1 M2CzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTRwOEmwOFgh|ryP NUTKflRiW0GQR1XS
A3-KAW MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\xUFdbUUN3ME20Mlk4OzV{IN88US=> NFTRZmZUSU6JRWK=
CAS-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\pZmlEPTB;ND65PVkxQCEQvF2= MUXTRW5ITVJ?
NBsusSR NUHZdXBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTVwMEO1NVQh|ryP NUS5ZW5ZW0GQR1XS
KM12 NIPTPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTVwMkm4Nlch|ryP NXjFc3ZjW0GQR1XS
NCI-H1155 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zFU2lEPTB;NT6zPFE5PSEQvF2= NUPKc|JNW0GQR1XS
EFM-19 M4PzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVv6fIlPUUN3ME21MlQyPzN5IN88US=> NIHFXGVUSU6JRWK=
D-392MG MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTVwNUe4OFkh|ryP MYjTRW5ITVJ?
JVM-3 M1G1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTVwN{KzNlUh|ryP NIn4OmFUSU6JRWK=
EW-16 NELLeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e4T2lEPTB;NT63OVU5OyEQvF2= MWLTRW5ITVJ?
KARPAS-45 M1jKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnnWXBLUUN3ME21Mlg1OzJ3IN88US=> NXfHPFdDW0GQR1XS
NCI-H28 Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17SPGlEPTB;NT64O|kyQCEQvF2= NIjxWY1USU6JRWK=
COLO-829 NUToXlFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvpS|FxUUN3ME21MlkyPTB2IN88US=> NX6yVI1CW0GQR1XS
KM-H2 M{npdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzM[I9KSzVyPUWuPVI{QTVizszN NV;ibJE{W0GQR1XS
NCI-H82 NEn3XGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXveZZKSzVyPUWuPVI4PzFizszN NIHOVFVUSU6JRWK=
OAW-42 M1XURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH1OG1KSzVyPUWuPVg5OjFizszN M1TpeHNCVkeHUh?=
A704 MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTZwMUC1O|Qh|ryP Mn;uV2FPT0WU
NCI-H1048 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1L5O2lEPTB;Nj6xNFU6QSEQvF2= MkXPV2FPT0WU
LOXIMVI MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDGcFF7UUN3ME22MlEyOjR6IN88US=> NHPvcoNUSU6JRWK=
MKN45 M1u2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTZwMk[wNVYh|ryP NGjNbHZUSU6JRWK=
D-502MG NIS5RnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHMd|FKUUN3ME22MlI5QDV5IN88US=> M3uzd3NCVkeHUh?=
HUTU-80 NHuzdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHBTWM2OD14LkSxOlg5KM7:TR?= NH75SXpUSU6JRWK=
S-117 M4DXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUS5[WxoUUN3ME22MlUxOjZ5IN88US=> MlLjV2FPT0WU
HCC1569 NFT5OoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\STWM2OD14LkWzO|M4KM7:TR?= NH\RV3lUSU6JRWK=
J-RT3-T3-5 NUj1U24zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTZwNUS1O|Ih|ryP NUfhNY9VW0GQR1XS
OC-314 M3L6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXNTWM2OD14LkmxNVU6KM7:TR?= M4rvWHNCVkeHUh?=
SNU-449 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrqSYNKSzVyPUeuNFExPzJizszN M2nOOXNCVkeHUh?=
NCI-H720 Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETZTndKSzVyPUeuNVk{PDVizszN NGKxc5FUSU6JRWK=
KP-N-YS M3fINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTdwMkC3NkDPxE1? M{H0dXNCVkeHUh?=
IGROV-1 Mo\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n6cmlEPTB;Nz6zNlM5PiEQvF2= NUXp[|F1W0GQR1XS
SK-PN-DW NFzRWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTZTWM2OD15LkS4NVUh|ryP MYnTRW5ITVJ?
HCC1419 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfqTWM2OD15LkWzJO69VQ>? M1rrOHNCVkeHUh?=
HAL-01 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTdwNkC2OFQh|ryP NF7IeG1USU6JRWK=
HCC2998 NGjURVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTdwNkC3OFMh|ryP MWHTRW5ITVJ?
SK-N-FI M3y1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3tSJBKSzVyPUeuOlMxOzNizszN Mk\PV2FPT0WU
GI-ME-N MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTdwNkS5N|Qh|ryP MkDJV2FPT0WU
SW1088 NV60OJhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\KeWlEPTB;Nz62OVgzPiEQvF2= NHjXdmxUSU6JRWK=
IA-LM M2XaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LiZWlEPTB;Nz62PFYyOyEQvF2= Mn7CV2FPT0WU
SK-NEP-1 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDzZmNKSzVyPUeuOlk3OSEQvF2= NUPsV2dnW0GQR1XS
MDA-MB-415 M4nIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTdwOEmxPFYh|ryP MmXYV2FPT0WU
COLO-800 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LENGlEPTB;Nz65OFQ6OiEQvF2= NGHMW4hUSU6JRWK=
NCI-H2228 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRThwMUW3PFMh|ryP NF3uU5dUSU6JRWK=
D-423MG MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXxOHZXUUN3ME24MlIyPzJizszN NFvpO2ZUSU6JRWK=
TE-1 NYLXWFRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fkOGlEPTB;OD60OFMyPiEQvF2= Mlq5V2FPT0WU
NOS-1 NHnMVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfOZoVKSzVyPUiuOVE2OzRizszN NH;COGdUSU6JRWK=
8505C NXK1cIdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LYdWlEPTB;OD62OFgzPCEQvF2= M{LPNHNCVkeHUh?=
HEC-1 NHHJbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfyZmZKSzVyPUiuO|g1OzlizszN Mm\jV2FPT0WU
TE-11 M3O5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLUSHRWUUN3ME24Mlk6PTVzIN88US=> MYHTRW5ITVJ?
CTB-1 NWK2SlllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HH[WlEPTB;OT6wNVQ{OyEQvF2= M4H2THNCVkeHUh?=
TGBC11TKB MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH2[oFKSzVyPUmuNFIzPDFizszN NWfmfIlLW0GQR1XS
NB17 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzTTWM2OD17LkG4PFch|ryP MXfTRW5ITVJ?
Becker MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\qcmlEPTB;OT60NVk1PCEQvF2= M37X[XNCVkeHUh?=
SN12C MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTlwNEWyN|Qh|ryP MoPFV2FPT0WU
COLO-320-HSR MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjQUVBKSzVyPUmuOlAzOzdizszN MV3TRW5ITVJ?
D-283MED NEG2N4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PwVWlEPTB;OT62N|A4OiEQvF2= NYPFTmNPW0GQR1XS
D-263MG NHjvepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLuPZJRUUN3ME25Mlg{Ozh2IN88US=> M{LBc3NCVkeHUh?=
MEL-JUSO Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLFTVRIUUN3ME25MlkxOTJ5IN88US=> NHLK[GhUSU6JRWK=
T98G NUTSSWdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PIemlEPTB;OT65NFIxOyEQvF2= NGW4WHBUSU6JRWK=
HLE NHuyRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDDWVRKSzVyPUmuPVA6ODlizszN Mn\uV2FPT0WU
Ca9-22 M1vn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DYVGlEPTB;MUCuNFY3PSEQvF2= M2fFUnNCVkeHUh?=
OS-RC-2 MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfpeG9yUUN3ME2xNE4yODR3IN88US=> NFTxRVlUSU6JRWK=
T47D NUDEOYI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j5R2lEPTB;MUCuNVU2KM7:TR?= MVjTRW5ITVJ?
GI-1 NHnjO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFyLkO1N|Mh|ryP M1HQR3NCVkeHUh?=
NUGC-3 MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFyLkS0NFIh|ryP MVvTRW5ITVJ?
MDA-MB-361 NFqyN4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TXfmlEPTB;MUCuOFQ{OiEQvF2= NFKxeGJUSU6JRWK=
SCC-15 NVP1c41mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFyLkS3NVgh|ryP Mk\OV2FPT0WU
KS-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTDU5BOUUN3ME2xNE43OzBzIN88US=> NX3PWmI6W0GQR1XS
CAL-12T NUHNWmRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzUXJpKSzVyPUGwMlY{PjFizszN MXXTRW5ITVJ?
OVCAR-4 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFyLkewOlgh|ryP NIjPVpJUSU6JRWK=
HuP-T4 Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFzLkCzNlgh|ryP M3\nb3NCVkeHUh?=
NCI-H358 MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTnTWM2OD1zMT6yOlU4KM7:TR?= NHWxNGxUSU6JRWK=
HO-1-N-1 MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFzLkOzPVgh|ryP MXLTRW5ITVJ?
NH-12 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFzLkWzO|gh|ryP MkLMV2FPT0WU
MOLT-4 Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G5OmlEPTB;MUGuOVk5PSEQvF2= MoizV2FPT0WU
K-562 NHXldWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fyfmlEPTB;MUGuO|I1QCEQvF2= M1;KWHNCVkeHUh?=
ES6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFzLki1PFEh|ryP MlvoV2FPT0WU
RO82-W-1 NEnW[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUntfZBSUUN3ME2xNU46ODZ2IN88US=> MXXTRW5ITVJ?
Ramos-2G6-4C10 NWHnfoEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PafWlEPTB;MUGuPVMzKM7:TR?= MVzTRW5ITVJ?
23132-87 NGXQR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF{LkC4NlEh|ryP MkL6V2FPT0WU
A549 NEm5[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXMUGhKSzVyPUGyMlMzQDVizszN M4\CS3NCVkeHUh?=
NCI-H23 MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle4TWM2OD1zMj61NFI3KM7:TR?= NFrMTY5USU6JRWK=
H9 MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF{LkW1O|ch|ryP MX;TRW5ITVJ?
LB771-HNC NXzHfnVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTF{Lke2OUDPxE1? M4HxNnNCVkeHUh?=
QIMR-WIL NV\vXXRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjObJlKSzVyPUGyMlgzPThizszN M{LEPXNCVkeHUh?=
HSC-3 M{PPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF{LkmyO|Yh|ryP MmX6V2FPT0WU
PFSK-1 NFWzSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17IfmlEPTB;MUKuPVUxPyEQvF2= NETqNJFUSU6JRWK=
ETK-1 NH2wNYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF|LkC3O|kh|ryP MXPTRW5ITVJ?
SW1710 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vtXmlEPTB;MUOuN|Y1OSEQvF2= MXTTRW5ITVJ?
COLO-684 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoX0TWM2OD1zMz60OVQyKM7:TR?= M{CybnNCVkeHUh?=
RPMI-7951 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXTWGRbUUN3ME2xN{42OTN4IN88US=> NY\odlV5W0GQR1XS
A101D Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETLWnRKSzVyPUGzMlU{PDlizszN NEHBNJdUSU6JRWK=
KE-37 Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvLOoJKSzVyPUGzMlU5QDdizszN MoPMV2FPT0WU
SiHa NY\FPY5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvTV4RKSzVyPUGzMlg{PDZizszN NV\6[|BuW0GQR1XS
NCI-H226 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrsTWM2OD1zMz64PFA5KM7:TR?= NYHPOZdTW0GQR1XS
DB NUnLRW1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K5dWlEPTB;MUOuPVkzQCEQvF2= NVHFb5hSW0GQR1XS
HT-1197 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXURoJtUUN3ME2xOE4xQDB7IN88US=> NIrzUWtUSU6JRWK=
SBC-5 M{PhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fudmlEPTB;MUSuNVM3OiEQvF2= NVjZblE6W0GQR1XS
VMRC-RCZ NET2W2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvVeZk3UUN3ME2xOE42Pzd2IN88US=> MXTTRW5ITVJ?
697 NY\pNFhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7yTWM2OD1zND62Nlch|ryP NH:2S2NUSU6JRWK=
OMC-1 MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTGNZJ5UUN3ME2xOE44QDh6IN88US=> NHfSeWxUSU6JRWK=
SKG-IIIa NGfn[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PWc2lEPTB;MUSuPFAxOSEQvF2= NXv0T3J6W0GQR1XS
DOK M17ROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jrW2lEPTB;MUSuPVk{OyEQvF2= M4f3eXNCVkeHUh?=
NCI-H2029 M4jLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL2TWM2OD1zNT6zOlAzKM7:TR?= NVPxRWIxW0GQR1XS
NCI-H2009 M37RPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTF3LkWwPVUh|ryP NILETodUSU6JRWK=
LK-2 M37QV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK1eFlKSzVyPUG1MlY1PDlizszN MVTTRW5ITVJ?
NCI-H661 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXHTWM2OD1zNT65NFc2KM7:TR?= M2nqcnNCVkeHUh?=
GT3TKB NH7kSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG4b|c6UUN3ME2xOk4xPjd4IN88US=> MX;TRW5ITVJ?
GP5d Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvacnNKSzVyPUG2MlM1OiEQvF2= M3fqSXNCVkeHUh?=
SK-MEL-2 NGLuT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF4LkS0PFUh|ryP MV3TRW5ITVJ?
SK-UT-1 NGK0ZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm2TWM2OD1zNj61OlUh|ryP M{ftfnNCVkeHUh?=
NB7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHmTWM2OD1zNj62PVcyKM7:TR?= M4rVNXNCVkeHUh?=
NCI-H460 M{XhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvZSXZNUUN3ME2xOk44OzJ4IN88US=> NHHBU|dUSU6JRWK=
8305C MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\hTWM2OD1zNj63PFc4KM7:TR?= MYXTRW5ITVJ?
CaR-1 MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF4LkixNVEh|ryP Ml;NV2FPT0WU
D-247MG NIjPTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF4Lki2NlUh|ryP NV7HVG5tW0GQR1XS
LoVo M1vIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTITWM2OD1zNj65OFg5KM7:TR?= MWPTRW5ITVJ?
NCI-H2405 MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\WTWM2OD1zNz6xPVA5KM7:TR?= M3O3Z3NCVkeHUh?=
AU565 M4P2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPud2FKSzVyPUG3MlIzPSEQvF2= M1fXdXNCVkeHUh?=
OCI-AML2 M{\QV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF5LkWzNVch|ryP NXPXb4NUW0GQR1XS
22RV1 M3;iTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LsTWlEPTB;MUeuOVg5PCEQvF2= Ml;vV2FPT0WU
HT-144 NIPWRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF5Lk[1PVgh|ryP NYHKR4k{W0GQR1XS
HuO9 NVriOmYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC5WYtKSzVyPUG3MlcxOzFizszN MU\TRW5ITVJ?
Daoy MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF5LkexPFQh|ryP MlTqV2FPT0WU
SJRH30 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHXW2kyUUN3ME2xO{45PDh7IN88US=> NEHvOGpUSU6JRWK=
CHL-1 Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF5LkmyOFkh|ryP NITKOmJUSU6JRWK=
J82 NGL3N|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTMTWM2OD1zNz65OlM2KM7:TR?= MYXTRW5ITVJ?
COR-L23 NH;oV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW1emVKSzVyPUG4MlAxOTFizszN NFv0b4ZUSU6JRWK=
SNU-C2B MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHhWopKSzVyPUG4MlIzPzZizszN MnLBV2FPT0WU
NCI-H1770 MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[wWm9HUUN3ME2xPE41PjF3IN88US=> MkjqV2FPT0WU
MHH-PREB-1 M2\Mb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjMem1DUUN3ME2xPE42Pjl5IN88US=> M3f2WHNCVkeHUh?=
ES3 Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnUc4dKSzVyPUG4MlU5QDNizszN NEDUUFNUSU6JRWK=
MDA-MB-231 NEnBPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHtSpJKSzVyPUG4MlY2ODJizszN NXT3SWpwW0GQR1XS
MN-60 NHe2TlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jsU2lEPTB;MUmuNFU6OiEQvF2= MmTZV2FPT0WU
EPLC-272H NXTLfZZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFWxZYFKSzVyPUG5MlM4ODhizszN MV7TRW5ITVJ?
SW948 NHq0WopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jRZWlEPTB;MUmuN|k{PCEQvF2= NGTxfHpUSU6JRWK=
MOLT-13 MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTF7LkS1OFYh|ryP MXzTRW5ITVJ?
HL-60 M2nOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJyLkKxOFEh|ryP NIXHWFdUSU6JRWK=
CP50-MEL-B MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHkXoNbUUN3ME2yNE41PzR6IN88US=> MVnTRW5ITVJ?
NTERA-S-cl-D1 NF20O|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PyR2lEPTB;MkCuOFk4QCEQvF2= MmGxV2FPT0WU
KINGS-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MluxTWM2OD1{MD63PVY4KM7:TR?= NULKPVR6W0GQR1XS
DOHH-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJyLkmwOkDPxE1? M2H0d3NCVkeHUh?=
BB65-RCC NF:5Z3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3tUYRKSzVyPUKwMlkzQDVizszN NHSwNGFUSU6JRWK=
NB12 NXyzfHBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXa[YdKSzVyPUKxMlA{QTRizszN MlPQV2FPT0WU
KY821 MoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzCPVMyUUN3ME2yNU42QDJizszN NX3lPGdnW0GQR1XS
PSN1 NWHuTpVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS0XIlbUUN3ME2yNU43PDV|IN88US=> MVPTRW5ITVJ?
EGI-1 NEfKbJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1m5c2lEPTB;MkGuO|Q2PCEQvF2= MWXTRW5ITVJ?
CTV-1 Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\oTWM2OD1{Mj6zNFMyKM7:TR?= MUXTRW5ITVJ?
TI-73 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjQUHRKSzVyPUKyMlM1QThizszN MonaV2FPT0WU
LCLC-103H NIDlSWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ{LkS3OVIh|ryP M1PSO3NCVkeHUh?=
D-542MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XrbWlEPTB;MkKuOVU2QCEQvF2= M1PjSHNCVkeHUh?=
ATN-1 MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL3TWM2OD1{Mj62OFM6KM7:TR?= NFnWRZBUSU6JRWK=
SK-MEL-1 M2e3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJ{LkizOlgh|ryP MVrTRW5ITVJ?
HDLM-2 NUK5bXFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDvT5BQUUN3ME2yN{4yPDd6IN88US=> MYTTRW5ITVJ?
UM-UC-3 NIrLSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vwPWlEPTB;MkOuNVk1PCEQvF2= MmLJV2FPT0WU
NCI-H1573 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVK5bIdoUUN3ME2yN{41PjhzIN88US=> NVyxPHVxW0GQR1XS
NCI-H520 MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofmTWM2OD1{Mz60PVQ5KM7:TR?= NYPqOnVtW0GQR1XS
ESS-1 NYHtN2lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr3T21PUUN3ME2yN{45ODV7IN88US=> MnrIV2FPT0WU
COR-L88 NXXrZ4p3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37pbWlEPTB;MkOuPVQ4PSEQvF2= NUPQTVF[W0GQR1XS
TGBC24TKB NVKxe|Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;PXmlEPTB;MkSuNFMyOiEQvF2= MnG2V2FPT0WU
HCC1937 MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJ2LkGg{txO NG\PfnhUSU6JRWK=
RS4-11 M1jacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJ2LkG0NkDPxE1? NHLC[GJUSU6JRWK=
HCC38 NVnLWJA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XDXWlEPTB;MkSuNlM6PCEQvF2= MWrTRW5ITVJ?
RPMI-2650 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDv[ZBvUUN3ME2yOE43OTZ{IN88US=> NXjMZWRwW0GQR1XS
P12-ICHIKAWA MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXxTXNKSzVyPUK0MlYzPThizszN MkPNV2FPT0WU
YAPC M1zWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfZO|g2UUN3ME2yOE45OjF2IN88US=> M{HBOnNCVkeHUh?=
NB13 MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M132O2lEPTB;MkWuNlYyOSEQvF2= M3\BSnNCVkeHUh?=
SK-N-AS MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LvWGlEPTB;MkWuPFU5PCEQvF2= NEnsSpJUSU6JRWK=
SK-N-DZ NY\qWnJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[4TWM2OD1{Nj6wOFkh|ryP MYjTRW5ITVJ?
LS-411N NXHtTI0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv0N5JKSzVyPUK2MlIxOzhizszN NHu2eWRUSU6JRWK=
NCI-H810 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvqeWFiUUN3ME2yOk4{OTF{IN88US=> MlXyV2FPT0WU
NCI-SNU-1 NIG4bZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnpVoFVUUN3ME2yOk42PDV2IN88US=> NEf1OHpUSU6JRWK=
HH NYT0bnlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfW[lFKSzVyPUK2MlU2OjlizszN MX\TRW5ITVJ?
U-2-OS NXnlW4JvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrKTWM2OD1{Nj63N|gzKM7:TR?= NInnO3VUSU6JRWK=
SF539 M1vXeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHUVoRKSzVyPUK2MlgxOThizszN NVeye3VKW0GQR1XS
NCI-H2052 Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPuTI1KSzVyPUK3MlA5PiEQvF2= NVvMS5ZGW0GQR1XS
A673 NWH3d|JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17lS2lEPTB;MkeuNlExOiEQvF2= M2K3OnNCVkeHUh?=
WM-115 NUfQd5k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfFRZl7UUN3ME2yO{44PzZ5IN88US=> M33jTXNCVkeHUh?=
SW48 M3PNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4CyT2lEPTB;MkeuPFAxPSEQvF2= NFLPNIFUSU6JRWK=
NOMO-1 Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj3N49VUUN3ME2yO{45PTN{IN88US=> MoPqV2FPT0WU
PC-3 MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXm[4QyUUN3ME2yO{45QTRzIN88US=> M2rLT3NCVkeHUh?=
UMC-11 MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLheZdKUUN3ME2yO{46OzR|IN88US=> M2nYOHNCVkeHUh?=
U-118-MG NYjuXFVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJ6LkCxNlMh|ryP NFHBT5dUSU6JRWK=
NCI-H2452 Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSxdWZTUUN3ME2yPE4xQDJ{IN88US=> M4H5eHNCVkeHUh?=
CAMA-1 MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnQWldKSzVyPUK4Mlg2PjRizszN MlztV2FPT0WU
MC-IXC NWXVXZIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHsbJJTUUN3ME2yPU4zOzZ4IN88US=> MYXTRW5ITVJ?
ES4 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJ7LkOxO|Ih|ryP NYLibFB5W0GQR1XS
BHT-101 MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfZVplKSzVyPUK5MlMzOSEQvF2= NXixU5RxW0GQR1XS
KP-4 NUnuRm1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfkTWM2OD1{OT61NVYh|ryP MVzTRW5ITVJ?
CAL-54 M{HjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDGWFZkUUN3ME2yPU42PDR3IN88US=> MVLTRW5ITVJ?
5637 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3myUWlEPTB;MkmuOlQzOSEQvF2= NHLMNYxUSU6JRWK=
MOLT-16 NXjMW5JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XvXWlEPTB;MkmuO|I3QSEQvF2= NWjNN4NDW0GQR1XS
Ca-Ski MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjVbWRRUUN3ME2yPU46PDZizszN NWnLVWJ5W0GQR1XS
AsPC-1 NH3uPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEOyTmVKSzVyPUOwMlAzOTJizszN MV;TRW5ITVJ?
MSTO-211H MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljNTWM2OD1|MD6xOUDPxE1? M{jC[nNCVkeHUh?=
L-428 M3TMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTFOlFDUUN3ME2zNE41ODVizszN NEDVNJJUSU6JRWK=
SW1463 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEGwOHJKSzVyPUOwMlU{QDNizszN MkS2V2FPT0WU
NCI-H1648 MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfBcWhKSzVyPUOwMlU2PzRizszN Mn65V2FPT0WU
CAKI-1 NVjwXVBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXFTWM2OD1|MD63O|AzKM7:TR?= MmX0V2FPT0WU
YKG-1 NVjBTIU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D4OGlEPTB;M{GuNFI3OyEQvF2= NUi4elA6W0GQR1XS
A2058 M{P2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zlUGlEPTB;M{GuNVE3PCEQvF2= Mk\IV2FPT0WU
A375 MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K1RmlEPTB;M{GuNVY6PiEQvF2= MVPTRW5ITVJ?
SNB75 MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXqR2h7UUN3ME2zNU4zPDN3IN88US=> M2LNRXNCVkeHUh?=
SK-HEP-1 NW[1bJY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\pTohKSzVyPUOxMlQzPzFizszN M2\sZXNCVkeHUh?=
ME-180 NYfHb2NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHh[GRqUUN3ME2zNU43PTR{IN88US=> MX;TRW5ITVJ?
NCI-H209 M3PkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTNzLkiyOFch|ryP MmLMV2FPT0WU
HC-1 NIq1XWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fIbGlEPTB;M{KuNVQ1PiEQvF2= NYjFNW1CW0GQR1XS
LB373-MEL-D NY\XO3Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP6TWM2OD1|Mj6xPVcyKM7:TR?= MYPTRW5ITVJ?
SNU-387 NFr3PZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnPPZJKSzVyPUOyMlMyQTFizszN M3:wZXNCVkeHUh?=
C32 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\obWlEPTB;M{KuN|M2OyEQvF2= NIflb5JUSU6JRWK=
EW-13 NYPHd3I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDRc5Z5UUN3ME2zNk46PDB6IN88US=> NIjsWY5USU6JRWK=
BFTC-905 NVL1S4EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTN|LkWxN|Yh|ryP NUDSN5JGW0GQR1XS
NCI-H1299 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTN|LkW2NlEh|ryP MkC3V2FPT0WU
LU-135 NEfzTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\hXpR5UUN3ME2zN{45ODFizszN MkLpV2FPT0WU
NCI-H2122 M{jocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP5TWM2OD1|Mz65PVY3KM7:TR?= M4nwO3NCVkeHUh?=
SK-LMS-1 M4PGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3PTWM2OD1|ND60NVA4KM7:TR?= NEPkR|JUSU6JRWK=
LNCaP-Clone-FGC NFHPT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLVPFdKSzVyPUO0Mlg2OTVizszN M{GzUnNCVkeHUh?=
NCI-H1092 NHXWfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLZTWM2OD1|NT6yO|Q4KM7:TR?= M3jDcnNCVkeHUh?=
MS-1 NXiwNnVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi4bIVKSzVyPUO1MlMxOzhizszN M{XVdXNCVkeHUh?=
KYSE-510 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDHTWM2OD1|NT61NFQzKM7:TR?= MWTTRW5ITVJ?
NCI-H1793 NEXD[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HGOWlEPTB;M{WuOlU1PSEQvF2= MoqwV2FPT0WU
MIA-PaCa-2 MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfqNVRKSzVyPUO2MlA1QTZizszN NV\NT5hEW0GQR1XS
EW-22 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPJUHhKSzVyPUO2MlQxPzJizszN M4DhRnNCVkeHUh?=
IGR-1 M2DC[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTN4LkixPFQh|ryP MmXCV2FPT0WU
HT-1080 NHm5RZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTN5LkGyOUDPxE1? NHHsZmhUSU6JRWK=
M14 NXPtPGlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTN5LkG2OFIh|ryP MXvTRW5ITVJ?
786-0 NF\aWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTN5LkK3PVQh|ryP NEjydVVUSU6JRWK=
MZ2-MEL NVHFNGdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO5UGcyUUN3ME2zO{41PTBzIN88US=> MkfVV2FPT0WU
NCI-H510A MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fPO2lEPTB;M{euPVQyOiEQvF2= Mn3KV2FPT0WU
LAN-6 NYXFeVAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN5Lkm1PFIh|ryP MYHTRW5ITVJ?
SW620 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXIb|ZyUUN3ME2zPE41QTd2IN88US=> MWXTRW5ITVJ?
LB2241-RCC NUWxR5FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnkNm5KSzVyPUO5MlgzODVizszN NV3ybHl2W0GQR1XS
Detroit562 NXTHZ4hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO2TWM2OD12MD6xNlY5KM7:TR?= NH;1fmFUSU6JRWK=
HN NGG2NnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPJTWM2OD12MD6xO|gzKM7:TR?= NF:5WoxUSU6JRWK=
HCT-15 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTRyLkW5NFch|ryP NVy4SXh2W0GQR1XS
C2BBe1 NV\xTVU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvp[WVKSzVyPUSwMlkyPTdizszN NVTXNmlkW0GQR1XS
A498 NVnaW2JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGzTWM2OD12MT6zNFE2KM7:TR?= NX3aeoh{W0GQR1XS
SK-MEL-24 MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHZN|FKSzVyPUSxMlQ4OjVizszN M2jLWnNCVkeHUh?=
OVCAR-5 MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInTdJJKSzVyPUSxMlc4PjdizszN MljYV2FPT0WU
NCI-H1792 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPpd2hKSzVyPUSxMlk5OjFizszN MXPTRW5ITVJ?
KOSC-2 NW\2[2FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv4UWxWUUN3ME20Nk4zPjl7IN88US=> Mk\2V2FPT0WU
Mo-T MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3q3SWlEPTB;NEKuPFk2QCEQvF2= MmfJV2FPT0WU
CFPAC-1 M3HzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGiwN3ZKSzVyPUSzMlQ6PDRizszN NFTjWFBUSU6JRWK=
CAL-51 NYLZZ3ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[w[INtUUN3ME20N{42PjB3IN88US=> MljKV2FPT0WU
RH-18 NIXDPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PnR2lEPTB;NEOuPFA2KM7:TR?= MYnTRW5ITVJ?
EC-GI-10 NVyxVVBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTR|LkizOFch|ryP MneyV2FPT0WU
HSC-2 NVf2fFFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL6TWM2OD12ND6wNFkh|ryP NVraVY5PW0GQR1XS
ML-2 NYPQN|JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrIWHJOUUN3ME20OU4zPjJzIN88US=> M1G5UnNCVkeHUh?=
KNS-81-FD MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTR3LkezOlUh|ryP NWXFdY5oW0GQR1XS
NB6 NUfvOIE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn1W45KSzVyPUS2MlEyOSEQvF2= M1rOTHNCVkeHUh?=
MCF7 NEXvcFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ixV2lEPTB;NE[uOVU{OyEQvF2= NH;zWYRUSU6JRWK=
P30-OHK M2\lSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7tNoZKSzVyPUS2MlgyOTdizszN MmjuV2FPT0WU
BPH-1 NUXsUnk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[zfWlEPTB;NE[uPVgxPSEQvF2= M1rGbXNCVkeHUh?=
U251 Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvUTWM2OD12Nj65PVQh|ryP MXjTRW5ITVJ?
MKN1 MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPyOlJ5UUN3ME20O{42OTN5IN88US=> NUWzV2FbW0GQR1XS
A431 NHz0eIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTR5LkizN|gh|ryP MWPTRW5ITVJ?
C8166 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jl[mlEPTB;NEmuNlA{QSEQvF2= NYr6OZdoW0GQR1XS
HEL MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTR7LkSwOlQh|ryP M{nRNHNCVkeHUh?=
RMG-I MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;XS2lEPTB;NEmuOFQ1PCEQvF2= MlTQV2FPT0WU
CAL-72 Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrNUVZKSzVyPUS5MlYxPzVizszN MlHpV2FPT0WU
SW962 M4jPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X2XmlEPTB;NEmuPVM{OiEQvF2= NEjCcJlUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 0.5% CMC 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer June 2017 --
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer September 2016 Phase 1|Phase 2
NCT02859012 Recruiting Recurrent ACC, metastaticACC, Unreaectable ACC Seoul National University Hospital September 2016 Phase 2
NCT02853331 Recruiting Renal Cell Carcinoma Merck Sharp & Dohme Corp. September 2016 Phase 3
NCT02762513 Recruiting Squamous Cell Carcinoma of the Head and Neck University of Michigan Cancer Center|National Comprehensive Cancer Network August 2016 Phase 2
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID